Patent Issuance $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a patent by the United States Patent and Trademark Office (USPTO) for the…
FH.NEO
Meeting with the FDA $18.123M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has held a pre-investigational new drug application (PIND) meeting with the FDA Division…
A Transformative Year $18.123M Market Capitalization Filament Health Corp. (FH.NE) today released its Q4 2021 financial results and has provided operational highlights for the period ended December 31, 2021….
Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic…
Psychedelics are once again hinting at a major reversal. With Cannabis stocks essentially confirming reversal breakouts, will psychedelics be able to join? It comes down to that catalyst. Will…
Ben Lightburn, CEO, director and co-founder of Filament Health (FH.NEO), a Canadian-based psychedelics company focused on the natural extraction and clinical delivery of psilocybin compounds, faces off with Equity.Guru…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Two for Two $23.066M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for the…
Standardizing Psychedelic-Assisted Therapy $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into a licensing agreement with ATMA Journey Centers. Under the agreement, Filament has…
Back in October, Zuckerberg, seeing plunging user numbers and fading growth, desperately renamed Facebook, once the world’s foremost purveyor of misinformation and unethical aggregator of personal data, to Meta,…